[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"fentanyl\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:fentanyl":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,66,104,132,162,191,218,242,275,306,339],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":36,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":65},"100601587","phase-1-fentanyl-intranasal-for-retinopathy-of-prematurity-screening-in-preterm-infants-100601587",false,"NCT07112430","Fentanyl Intranasal for Retinopathy of Prematurity Screening in Preterm Infants","Intranasal Fentanyl to Reduce Pain Intensity Associated With Retinopathy of Prematurity Screening in Preterm Infants: A Randomized Control Trial","FIREFLY","Inclusion Criteria\n\n* Preterm infants born ≤31 weeks gestational age and\u002For with birth weight \\\u003C1250 g\n* Scheduled to undergo routine retinopathy of prematurity (ROP) screening as part of standard NICU care\n* Clinically stable at the time of screening, defined as not requiring acute resuscitative support (no bag-mask ventilation, intubation, or chest compressions within the preceding 24 hours) and maintaining stable cardiorespiratory parameters on baseline respiratory support\n* Written informed consent obtained from a parent or legally authorized representative\n\nExclusion Criteria\n\n* Congenital anomalies or conditions affecting the nasal passages that would interfere with intranasal drug administration\n* Receipt of systemic opioids, benzodiazepines, barbiturates, or other sedative\u002Fanalgesic medications within 24 hours prior to the ROP examination\n* Known hypersensitivity or prior adverse reaction to fentanyl","ALL",{"count":19,"type":20},58,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","The goal of this clinical trial is to learn whether intranasal fentanyl (a pain medicine given as a nasal spray) can reduce pain and is safe to use during routine eye examinations for retinopathy of prematurity (ROP) in preterm infants. ROP is an eye condition that can affect babies born too early and requires regular eye examinations. The main questions this study aims to answer are: Does intranasal fentanyl lower pain during ROP screening? Is intranasal fentanyl safe for preterm infants? Researchers will compare intranasal fentanyl with a placebo (a saltwater spray that contains no medicine) to determine whether the medicine lowers pain during ROP screening.\n\nParticipants will receive either intranasal fentanyl or placebo before their routine ROP eye examination, in addition to the standard comfort measures normally used during the procedure. Researchers will measure participants' pain and monitor their heart rate, oxygen levels, and any side effects during and after the examination.",[27,28,29,30,31,32,33,34,35],"Neonatal Pain","Retinopathy of Prematurity (ROP)","Pain Management","Infant, Premature","Fentanyl","Infant, Newborn","Neonatal Intensive Care Units","Analgesia","Intranasal Drug Administration",[37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52],"intranasal fentanyl","fentanyl","neonatal analgesia","procedural pain","ROP screening","Retinopathy of Prematurity","Preterm infants","Premature infants","infant pain","Non-invasive analgesia","Opioid analgesia","Intranasal drug delivery","Neonatal intensive care","NICU","Pain management in neonates","Infant procedural sedation","NOT_YET_RECRUITING","2026-06-26",{"date":56,"type":57},"2026-06-30","ACTUAL",{"date":59,"type":20},"2026-09-09",{"date":61,"type":20},"2028-06-01",{"name":63,"class":64},"Marsha Campbell-Yeo","OTHER",1,{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":17,"minAge":73,"maxAge":4,"enrollmentInfo":74,"targetDuration":4,"studyType":21,"phases":76,"briefSummary":78,"conditions":79,"keywords":89,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":65},"100635703","dexmedetomidine-and-propofol-for-sedation-in-cataract-surgery-100635703","NCT07556133","Dexmedetomidine and Propofol for Sedation in Cataract Surgery.","Dexmedetomidine vs Propofol for Sedation in Cataract Surgery : a Prospective Randomized Controlled Trial.","Inclusion Criteria:\n\n* Adults undergoing cataract surgery\n\nExclusion Criteria:\n\n* Severe hepatic insufficiency\n* Third degree AV block\n* Patient refusal","18 Years",{"count":75,"type":20},1000,[77],"NA","The goal of this prospective, randomized, single-blinded is to learn if there is an ideal sedation protocol in cataract surgery in adults.\n\nThe main questions it aims to answer are:\n\n* Does the combination of Dexmedetomidine and Propofol affect significantly Ramsay sedation scale, compared to Dexmedetomidine and compared to Propofol?\n* How does each sedation protocol affect hemodynamics? (Heart rate and blood pressure)\n* Are respiratory events more common in a certain group?\n* Is the surgeon's satisfaction similar among groups?\n* Are adverse effects (bradycardia, hypotension, nausea) more common in a certain group?\n\nResearchers will compare 3 sedation protocols : Dexmedetomidine versus Propofol versus the combination of these 2 drugs and to see if one protocol is overall superior to the others. Fentanyl will also be used in all 3 sedation protocols.\n\nParticipants will :\n\n* Receive one of these three protocols\n* Be operated for one or both eyes\n* Monitored during the whole surgery and in the recovery room\n* Be evaluated by the Ramsay sedation scale by a trained Anesthesiologist or CRNA during surgery and in the recovery room Surgeons will be asked about how much they were satisfied.",[80,81,82,83,84,85,31,86,87,88],"Sedation","Cataract","Hemodynamic","Hemodynamic Changes","Dexmedetomidine","Propofol Dosage","Bradycardia","Tachycardia","Nausea and Vomiting",[90,81,91,92,93],"Dexmedetomidine and propofol in cataract surgery","sedation","Dexmedetomidine in cataract surgery","Sedation for cataract surgery","RECRUITING","2026-04-21",{"date":97,"type":57},"2026-04-29",{"date":99,"type":57},"2025-11-09",{"date":101,"type":20},"2026-12-09",{"name":103,"class":64},"Saint-Joseph University",{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":17,"minAge":111,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":21,"phases":114,"briefSummary":115,"conditions":116,"keywords":4,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":65},"100612024","ketamine-lidocaine-versus-ketamine-fentanyl-for-induction-of-anesthesia-in-patients-with-left-ventricular-systolic-dysfunction-undergoing-elective-coronary-artery-bypass-100612024","NCT07248202","Ketamine-lidocaine Versus Ketamine-fentanyl for Induction of Anesthesia in Patients With Left Ventricular Systolic Dysfunction Undergoing Elective Coronary Artery Bypass","A Comparison Between the Effect of Ketamine-lidocaine Versus Ketamine-fentanyl for Induction of Anesthesia on Cerebral Perfusion Guided by Near Infra-red Spectroscopy in Patients With Coronary Artery Disease and Left Ventricular Systolic Dysfunction Undergoing Elective Coronary Artery Bypass Graft Surgery: (A Randomized Controlled Study)","Inclusion Criteria:\n\n* patients with coronary artery disease\n* with moderate to severe left ventricular dysfunction (ejection fraction \\\u003C 40%),\n* scheduled for elective CABG surgery\n\nExclusion Criteria:\n\n* associated chronic stroke, TIA , carotid occlusive disease( due to abnormal vasomotor activity), patients with known neurological impairment (cerebral infarction , dementia ), significant carotid artery stenosis ,\n* valvular heart disease,\n* persistent arrhythmias,\n* congestive cardiac failure,\n* on mechanical ventilation,\n* intra-aortic balloon pump,\n* emergency surgery,\n* and those with known allergy to any of the study's drugs,\n* severe systemic non-cardiac disease and\n* patients with baseline NIRS reading \\\u003C 60%\n* Patients with dementia or visual or auditory impairment","21 Years",{"count":113,"type":20},40,[77],"This study compares ketamine\u002Ffentanyl versus ketamine\u002Flidocaine in term of their impact on cerebral perfusion during CABG. No prior data address these effects, and the goal is to identify the induction regimen that better preserves cerebral oxygenation.",[117,118,119,120,121,31,122],"Coronary Artery Disease (CAD)","Left Ventricular (LV) Systolic Dysfunction","Induction Anesthesia","Coronary Bypass Graft Surgery","Ketamine","Lidocaine","2026-03-15",{"date":125,"type":57},"2026-03-17",{"date":127,"type":57},"2025-12-01",{"date":129,"type":20},"2026-07",{"name":131,"class":64},"Cairo University",{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":138,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":17,"minAge":73,"maxAge":4,"enrollmentInfo":140,"targetDuration":4,"studyType":21,"phases":142,"briefSummary":144,"conditions":145,"keywords":147,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":65},"100629042","phase-4-comparing-outpatient-treatment-retention-among-individuals-using-fentanyl-randomized-to-low-dose-and-direct-to-inject-buprenorphine-initiation-100629042","NCT07469501","Comparing Outpatient Treatment Retention Among Individuals Using Fentanyl Randomized to Low-dose and Direct-to-inject Buprenorphine Initiation","Improving Buprenorphine Initiation Among Individuals With Opioid Use Disorder Using Fentanyl","COPILOT","Inclusion Criteria:\n\n* Age ≥ 18 years of age at Visit 1.\n* Documentation of an OUD diagnosis as evidenced by meeting two or more of the DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, 5th Edition) Criteria for Opioid Use Disorder\n* Self-reported daily use of fentanyl ≥ 5 out of the past 7 days at baseline,\n* Fentanyl-positive urine drug screening at baseline,\n* Interest in stopping or reducing fentanyl use,\n* Publicly insured through San Francisco Medicaid or Medicare and therefore able receive buprenorphine prescription dispensing through Community Behavioral Health Services (CBHS) Pharmacy\n\nExclusion Criteria:\n\n* Currently nursing, pregnant, or anticipating pregnancy in the next 6 months\n* Methadone-positive urine drug screening at baseline\n* Buprenorphine-positive urine drug screening at baseline\n* Be unable to provide any locator or contact information at least one contact in addition to themselves\n* Any pending legal action that could prevent participation in study activities\n* Presence of a condition or abnormality that, in the opinion of the Investigator, would compromise the safety of the patient or the quality of the data (e.g., acute psychosis), or cognitive impairment (e.g., dementia)",{"count":141,"type":20},50,[143],"PHASE4","The goal of this pragmatic randomized controlled trial is to compare treatment outcomes of two strategies for initiating buprenorphine treatment (low-dose initiation and direct-to-inject) in adults with opioid use disorder (OUD) who use fentanyl. This study aims to:\n\n1. Compare effectiveness of each strategy on treatment retention in a real world, clinical setting, and\n2. Assess differences between strategies in patient-reported outcomes, including withdrawal symptoms, cravings, drug use, treatment satisfaction, and overall acceptability.\n\nParticipants will:\n\n1. Be randomized to initiate buprenorphine via a low-dose initiation or direct-to-inject protocol at an outpatient buprenorphine clinic,\n2. Keep a diary of craving and withdrawal symptoms for the first 7 days after initiation, and\n3. Visit the outpatient clinic 7, 30, and 90 days after initiation for urinary drug screen and follow-up surveys.",[146,31],"Opioid Use Disorder",[148,149,150,151,152],"Buprenorphine initiation","Low-dose initiation","Direct-to-inject initiation","Medication for opioid use disorder","Outpatient treatment for opioid use disorder","2026-03-10",{"date":155,"type":57},"2026-03-13",{"date":157,"type":20},"2026-06",{"date":159,"type":20},"2027-05",{"name":161,"class":64},"University of California, San Francisco",{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":166,"acronym":4,"eligibilityCriteria":167,"healthyVolunteers":11,"sex":17,"minAge":168,"maxAge":169,"enrollmentInfo":170,"targetDuration":4,"studyType":21,"phases":172,"briefSummary":173,"conditions":174,"keywords":178,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":65},"100626427","fentanyl-versus-opioid-free-multimodal-analgesia-for-perioperative-pain-control-in-children-with-mild-to-moderate-obstructive-sleep-apnea-100626427","NCT07435493","Fentanyl Versus Opioid Free Multimodal Analgesia for Perioperative Pain Control in Children With Mild to Moderate Obstructive Sleep Apnea","Inclusion Criteria:\n\n* Children aged 5-10 years.\n* Diagnosed with mild to moderate Obstructive Sleep Apnea (apnea-hypoxia index 1-10).\n* Scheduled for elective adenotonsillectomy.\n* American Society of Anesthesiologists physical status I-II.\n\nExclusion Criteria:\n\n* Severe Obstructive Sleep Apnea (apnea-hypoxia index \\>10).\n* Known allergies to study medications.\n* Patient with predicted difficult air way (Mallampatti 3\\&4).\n* History of opioid use or chronic pain syndromes.\n* Neurological or metabolic disorders affecting pain perception.\n* Parental refusal to consent.","5 Years","10 Years",{"count":171,"type":20},64,[77],"Emphasize that the usage of multimodal analgesia in managing perioperative pain in children with mild to moderate Obstructive Sleep Apnea undergoing adenotonsillectomy may achieve the same efficacy of fentanyl with less respiratory complications and less opioid-related side effects.",[175,176,31,177],"Adenotonsillectomy","Obstructive Sleep Apnea (OSA)","Opioid",[179,31,180,181],"opioid","obstructive sleep apnea","adenotonsillectomy","2026-02-23",{"date":184,"type":57},"2026-02-27",{"date":186,"type":20},"2026-11-30",{"date":188,"type":20},"2026-12-30",{"name":190,"class":64},"Ain Shams University",{"id":192,"slug":193,"hasResults":11,"nctId":194,"briefTitle":195,"officialTitle":196,"acronym":4,"eligibilityCriteria":197,"healthyVolunteers":11,"sex":17,"minAge":73,"maxAge":198,"enrollmentInfo":199,"targetDuration":4,"studyType":21,"phases":200,"briefSummary":201,"conditions":202,"keywords":4,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":65},"100614228","intrathecal-dexmedetomidine-fentanyl-combination-versus-fentanyl-alone-as-adjuvant-to-bupivacaine-in-spinal-anesthesia-for-above-knee-amputation-in-sarcomas-of-lower-extremity-100614228","NCT07276867","Intrathecal Dexmedetomidine-Fentanyl Combination Versus Fentanyl Alone as Adjuvant to Bupivacaine in Spinal Anesthesia for Above Knee Amputation in Sarcomas of Lower Extremity","Intrathecal Dexmedetomidine-Fentanyl Combination Versus Fentanyl Alone as Adjuvant to Bupivacaine in Spinal Anesthesia for Above Knee Amputation in Sarcomas of Lower Extremity: A Randomized, Comparative Study","Inclusion Criteria:\n\n* Age from 18 to 60 years.\n* Both sexes.\n* American Society of Anesthesiologists (ASA) physical status of II-III.\n* Height between 150-185 cm.\n* Body mass index between 18-35 kg\u002Fm².\n* Scheduled for above-knee amputation due to lower limb sarcomas.\n\nExclusion Criteria:\n\n* Allergy to any of the investigated drugs.\n* History of heart block, arrhythmia, or ongoing therapy with beta- or calcium channel- blockers, or angiotensin-converting-enzyme inhibitors.\n* Contraindications to spinal anesthesia.\n* Pregnancy or lactation.\n* Presence of psychiatric illness or chronic pain conditions.","60 Years",{"count":19,"type":20},[77],"The current work evaluated whether the combination of intrathecal dexmedetomidine and fentanyl provides superior postoperative analgesia to fentanyl alone when administered with hyperbaric bupivacaine.",[203,84,31,204,205,206,207,208],"Intrathecal","Bupivacaine","Spinal Anesthesia","Above Knee Amputation","Sarcomas","Lower Extremity","2025-11-30",{"date":211,"type":57},"2025-12-11",{"date":213,"type":57},"2025-10-20",{"date":215,"type":20},"2026-04-01",{"name":217,"class":64},"National Cancer Institute, Egypt",{"id":219,"slug":220,"hasResults":11,"nctId":221,"briefTitle":222,"officialTitle":223,"acronym":4,"eligibilityCriteria":224,"healthyVolunteers":11,"sex":17,"minAge":73,"maxAge":4,"enrollmentInfo":225,"targetDuration":4,"studyType":21,"phases":227,"briefSummary":228,"conditions":229,"keywords":4,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":65},"100603828","fentanyl-versus-ketorolac-as-an-adjuvant-to-peribulbar-block-for-anterior-segment-surgeries-100603828","NCT07141589","Fentanyl Versus Ketorolac as an Adjuvant to Peribulbar Block for Anterior Segment Surgeries","Fentanyl Versus Ketorolac as an Adjuvant to Peribulbar Block for Anterior Segment Surgeries, A Prospective Double-blinded Randomized Controlled Study","Inclusion Criteria:\n\n* Age over 18 years old.\n* Both sexes.\n* American Society of Anesthesiologists (ASA) physical status I-III.\n* Scheduled to undergo operations for anterior segment surgeries of the eye under local (peribulbar) anesthesia.\n\nExclusion Criteria:\n\n* Patient's refusal.\n* Known allergy or hypersensitivity to aspirin or nonsteroidal anti-inflammatory medications.\n* Patients with contraindications to local anesthetics, such as high axial length or patients with high preoperative intraocular pressure.\n* If cases develop severe pain intraoperatively from the start, necessitating rescue analgesia and sedation or requiring conversion to general anesthesia.\n* Infection at the site of injection.\n* Patients with coagulopathies or on anticoagulants.\n* Impaired renal function.",{"count":226,"type":20},168,[77],"This study aims to compare the efficacy of ketorolac and fentanyl as adjuvants to local anesthetics for anterior segment surgeries of the eye.",[31,230,231,232,233],"Ketorolac","Adjuvant","Peribulbar Block","Anterior Segment Surgeries","2025-08-19",{"date":236,"type":57},"2025-08-26",{"date":238,"type":57},"2024-08-25",{"date":240,"type":20},"2025-11-25",{"name":131,"class":64},{"id":243,"slug":244,"hasResults":11,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":248,"eligibilityCriteria":249,"healthyVolunteers":250,"sex":17,"minAge":73,"maxAge":198,"enrollmentInfo":251,"targetDuration":4,"studyType":21,"phases":253,"briefSummary":254,"conditions":255,"keywords":261,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":267,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":273,"locationsCount":65},"100601981","phase-4-d-fab-pour-trial-dexmedetomidine-vs-fentanyl-as-adjuvants-to-bupivacaine-on-postoperative-urinary-retention-100601981","NCT07117565","D-FAB-POUR Trial: Dexmedetomidine vs Fentanyl as Adjuvants to Bupivacaine on Postoperative Urinary Retention","Comparison of Intrathecal Dexmedetomidine Versus Intrathecal Fentanyl as Adjuvants to Bupivacaine on Post-Operative Urinary Retention in Lower Limb Surgery","D-FAB-POUR","Inclusion Criteria:\n\n* Adults aged 18 to 60 years\n* Scheduled for elective lower limb surgery under spinal anesthesia\n* Classified as American Society of Anesthesiologists (ASA) physical status II or III\n* Minimum height of 150 cm (to ensure uniform drug volume)\n* Able to understand the study procedures and provide written informed consent (in English or Nepali)\n\nExclusion Criteria:\n\n* Contraindications to spinal anesthesia (e.g., coagulopathy, infection at injection site, hemodynamic instability)\n* Known allergy or hypersensitivity to bupivacaine, fentanyl, or dexmedetomidine\n* Chronic pain conditions or long-term opioid use\n* Neurological, Cardiac, Renal, or uncontrolled diabetic conditions\n* Current treatment for prostatic pathology or use of alpha-2 blockers\n* Presence of a Foley's catheter preoperatively\n* Estimated surgical duration: \\>2.5 hours\n* Inability or unwillingness to provide informed consent",true,{"count":252,"type":20},190,[143],"This study aims to compare two medications, dexmedetomidine and fentanyl, when used alongside a commonly used spinal anesthetic called bupivacaine in patients undergoing lower limb surgery. The main focus of the study is to see which combination causes fewer problems with urination after surgery - a condition known as postoperative urinary retention (POUR). POUR can lead to discomfort, delayed recovery, and a need for catheterization. Dexmedetomidine is a newer drug that may help reduce this problem compared to fentanyl, which is more commonly used but may increase the risk of urinary retention. This trial will help determine which medication combination provides better pain relief while reducing urinary side effects. The study is being conducted as a randomized, double-blind trial at a hospital in Nepal and will include 190 adult patients.\n\n\\-",[205,256,84,31,257,204,258,259,260],"Postoperative Complications","Anesthesia, Spinal","POUR","Orthopedic Surgery","Urinary Retention Postoperative",[262,263,264,84,31,265],"Postoperative urinary retention","Spinal anesthesia","Intrathecal adjuvants","Perioperative complications","2025-08-09",{"date":268,"type":57},"2025-08-12",{"date":270,"type":20},"2025-09-15",{"date":272,"type":20},"2026-11-25",{"name":274,"class":64},"Tribhuvan University Teaching Hospital, Institute Of Medicine.",{"id":276,"slug":277,"hasResults":11,"nctId":278,"briefTitle":279,"officialTitle":280,"acronym":281,"eligibilityCriteria":282,"healthyVolunteers":11,"sex":17,"minAge":283,"maxAge":4,"enrollmentInfo":284,"targetDuration":4,"studyType":21,"phases":286,"briefSummary":287,"conditions":288,"keywords":291,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":297,"lastUpdatePostDateStruct":298,"startDateStruct":300,"completionDateStruct":302,"leadSponsor":304,"locationsCount":65},"100515003","phase-2-evaluating-tetrahydrocannabinol-as-an-adjunct-to-opioid-agonist-therapy-100515003","NCT05985850","Evaluating Tetrahydrocannabinol as an Adjunct to Opioid Agonist Therapy","Evaluating Tetrahydrocannabinol as an Adjunct to Opioid Agonist Therapy for Individuals Living With Opioid Use Disorder: A Phase II, Placebo-controlled, Blinded, Pilot Study to Assess Safety and Feasibility (THC-MMT)","THC-MMT","Inclusion Criteria:\n\n1. Individuals of at least 25 years of age or older;\n2. Diagnosed with OUD as per DSM-5 criteria;\n3. Initiated or re-initiated methadone-based OAT within the past 30 days prior to study entry;\n4. Cannabis-use experienced, defined as having used any amount of cannabis in the six months prior to the screening visit;\n5. Willing to only use study-provided cannabis as directed by study protocol, including abstention from non-study cannabis and cannabinoids;\n6. Agree to keep all study medication stored in a secure location and not to share\u002Fdistribute study medication to any other individual;\n7. If assigned female sex at birth:\n\n   1. Be of non-childbearing potential, defined as (i) postmenopausal (12 months of spontaneous amenorrhea and over 45 years of age); or (ii) documented surgical sterilization (i.e., tubal ligation, hysterectomy, or bilateral oophorectomy); or\n   2. If of childbearing potential, be willing to use an acceptable method of contraception throughout the study and have a negative pregnancy test at screening;\n8. Ability to understand and comply with study protocol procedures and to provide written informed consent.\n\nInclusion criteria for Phase 2\n\nIn addition to meeting all eligibility criteria outlined in Phase 1, participants will be eligible for Phase 2 provided they meet ALL the following criteria at Week 12:\n\n1. Participants who have not experienced a study medication-related serious adverse event during Phase 1;\n2. Participants who have not been lost to follow-up during Phase 1.\n\nExclusion Criteria:\n\n1. Any disabling, severe, or unstable medical or psychiatric condition that, in the opinion of the study physician, precludes safe participation in the study or the ability to provide fully informed consent, as assessed by medical and psychiatric history, physical examination, vital signs, and\u002For laboratory tests;\n2. Any severe or unstable co-morbid substance use disorder (e.g., delirium tremens, acute alcohol intoxication) that, in the opinion of the study physician, precludes safe participation in the study;\n3. Currently pregnant or breastfeeding, or planning to become pregnant;\n4. Known or suspected allergy or hypersensitivity to cannabinoids;\n5. History of respiratory disease, severe cardiovascular, cerebrovascular, renal or liver disease;\n6. Current or historic cannabis use disorder;\n7. Taking warfarin, clopidogrel, clobazam, theophylline, clozapine and olanzapine medications as they may interact with cannabinoids in a clinically significant manner if they cannot be switched to a different medication;\n8. Any personal or family history (first degree relative) of primary psychotic disorders (i.e., schizophrenia, schizoaffective disorder) as per DSM-5 criteria;\n9. Unable to abstain from driving any vehicle or operating machinery for at least 10 hours after taking the study medication. In cases where impairment persists beyond the initial 10-hour period, participants must continue to adhere to these restrictions until the impairment resolves;\n10. Actively participating in other interventional clinical trial(s);\n11. Incarcerated, pending legal action or other reasons that might prevent completion of the study.","25 Years",{"count":285,"type":20},24,[24],"This pilot study will evaluate the feasibility and safety of using 1:1 tetrahydrocannabinol (THC):Cannabidiol (CBD) cannabis oil as an adjunct therapy to methadone-based Opioid Agonist Therapy (OAT) for individuals with opioid use disorder (OUD) in a community setting.",[146,289,290,31],"Methadone","Cannabis",[292,146,290,293,177,294,295,296],"addiction","Harm Reduction","Pain","Quality of Life","Cannabidiol","2025-02-14",{"date":299,"type":57},"2025-02-17",{"date":301,"type":57},"2024-05-23",{"date":303,"type":20},"2027-03",{"name":305,"class":64},"BC Centre on Substance Use",{"id":307,"slug":308,"hasResults":11,"nctId":309,"briefTitle":310,"officialTitle":310,"acronym":311,"eligibilityCriteria":312,"healthyVolunteers":11,"sex":17,"minAge":73,"maxAge":4,"enrollmentInfo":313,"targetDuration":4,"studyType":21,"phases":315,"briefSummary":317,"conditions":318,"keywords":322,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":331,"startDateStruct":333,"completionDateStruct":335,"leadSponsor":337,"locationsCount":65},"100520028","phase-3-fentanyl-or-esketamine-for-traumatic-pain-fore-pain-trial-100520028","NCT06051227","Fentanyl or Esketamine for Traumatic PAIN (FORE-PAIN) Trial","FORE-PAIN","Inclusion Criteria:\n\n* age ≥ 18 years\n* pain has been caused by a trauma (any trauma mechanism) that occurred on the same day\n* Emergency Medical Services personnel determines that administration of a strong opioid or esketamine for analgesia is required\n* patient will be transported to a hospital\n\nExclusion Criteria:\n\n* (estimated) weight \\\u003C40 or \\>100 kg\n* subject does not understand Dutch or English\n* inability to report pain score\n* inability to give IN or IV medication\n* known severe cardiovascular disease\n* pre-eclampsia\n* Glasgow Coma Scale score \\\u003C 11\n* subject is known to have previously declined participation in medical research",{"count":314,"type":20},608,[316],"PHASE3","Fentanyl and esketamine are both standard of care for treatment of acute severe traumatic pain in the prehospital setting in the Netherlands. However, it is not known whether they are equally effective and safe. It is also not known whether intranasal (IN) administration of fentanyl or esketamine is equally effective and safe as intravenous (IV) administration.\n\nThe FORE-PAIN trial is a double-blind multi-arm randomized non-inferiority trial comparing Fentanyl IN, esketamine IV and esketamine IN (intervention arms) to fentanyl IV (comparator arm) for prehospital management of traumatic pain. The investigators hypothesize that all intervention arms provide analgesia that is non-inferior to the comparator arm, and that all study arms are equally safe.",[319,34,31,320,321],"Acute Pain Due to Trauma","Esketamine","Emergency Medical Services",[323,324,325,326,327,328,329],"Analgesics","Ketanest","Administration, intranasal","Administration, intravenous","Pain management","Drug-Related Side Effects and Adverse Reactions","Anesthetics","2025-01-28",{"date":332,"type":57},"2025-01-30",{"date":334,"type":57},"2024-01-11",{"date":336,"type":20},"2026-03",{"name":338,"class":64},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)",{"id":340,"slug":341,"hasResults":11,"nctId":342,"briefTitle":343,"officialTitle":343,"acronym":4,"eligibilityCriteria":344,"healthyVolunteers":11,"sex":17,"minAge":73,"maxAge":345,"enrollmentInfo":346,"targetDuration":4,"studyType":21,"phases":348,"briefSummary":349,"conditions":350,"keywords":353,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":355,"lastUpdatePostDateStruct":356,"startDateStruct":358,"completionDateStruct":360,"leadSponsor":362,"locationsCount":4},"100568782","phase-4-comparative-study-between-intrathecal-magnesium-sulfate-neostigmine-and-fentanyl-as-adjuvant-for-bubivacaine-in-postoperative-analgesia-in-lower-abdominal-surgeries-100568782","NCT06685705","Comparative Study Between Intrathecal Magnesium Sulfate, Neostigmine and Fentanyl as Adjuvant for Bubivacaine in Postoperative Analgesia in Lower Abdominal Surgeries","Inclusion Criteria:\n\n* • the American Society of Anesthesiologists (ASA) classification I-II\n\n  * Age \\>18 up to 55 years old\n  * Both sex\n  * Patients who will undergo lower abdominal surgeries\n\nExclusion Criteria:\n\n* • Patients' refusal.\n\n  * Patients with morbid obesity, cardiac diseases, hepatic diseases, renal diseases, diabetes mellitus with polyneuritis.\n  * Patients who were in risk-scoring groups American Society of Anesthesia III-IV.\n  * Hypertensive patients receiving therapy with adrenergic receptor antagonist, calcium channel blocker and\u002For angiotensin converting enzyme inhibitor.\n  * Patients with coagulation disorders, those receiving any anticoagulants.\n  * Any history of allergy to local anesthetic or other drugs used in the study, patients on examining drugs.\n  * Any contraindication to spinal anesthesia ( infection at puncture site and increased intracranial tension and Patients with psychiatric illness and neurologic diseases.","55 Years",{"count":347,"type":20},66,[143],"Lower abdominal surgeries often result in severe pain, which in turn can cause rapid and shallow breathing, retention of secretions and poor patient compliance. Justifiably, apart from the fear for the surgery outcome, patients are concerned mainly with postoperative pain. If treated inadequately, acute pain can have serious consequences for patient health mainly with postoperative complications, prolonged recovery and increased length of hospital stay. Higher levels of postoperative pain and pain distress are associated with increased morbidity, poorer functional recovery, and reduced quality of life.\n\nAim of the study To compare the duration, quality of analgesia, and side effects between intrathecal Magnesium sulfate, neostigmine and fentanyl as adjuvant for bubivacaine as postoperative analgesia in lower abdominal surgeries",[351,352,31],"Magnesium Sulfate","Neostigmine",[354],"lower abdominal surgeries","2024-11-11",{"date":357,"type":57},"2024-11-12",{"date":359,"type":20},"2024-12-01",{"date":361,"type":20},"2026-01-01",{"name":363,"class":64},"Assiut University"]